REG - Futura Medical PLC - Remuneration of Non-Executive Directors and TVR's

Futura MedicalAnnouncement

13/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250113:nRSM9639Sa&default-theme=true

RNS Number : 9639S  Futura Medical PLC  13 January 2025

13 January 2025

Futura Medical plc

("Futura" or the "Company")

Remuneration of Non-Executive Directors and Total Voting Rights

 

 

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company
developing a portfolio of innovative products for sexual health and pain
relief, announces the issue of 126,116 new ordinary shares of 0.2 pence each
("Ordinary Shares") in respect of the 2024 remuneration of its Non-Executive
Directors .

 

Remuneration of Non-Executive Directors

 

In accordance with the terms of their service agreements, the Non-Executive
Directors receive 25 per cent. of their remuneration in the form of Ordinary
Shares. For 2024, these were issued at 27.10 pence per share, being the
average closing mid-market price of the last 10 trading days of 2023 (as
announced via RNS on 17 January 2024).

 

The 126,116 new Ordinary Shares shall rank pari passu with the existing issued
Ordinary Shares of the Company and have been issued as follows:

 

 Director      Number of Ordinary Shares issued for 2024 remuneration  Total number of ordinary shares held  Percentage of the Company's resulting issued share capital
 Jeff Needham  55,600                                                  83,561                                0.01%
 Andrew Unitt  30,221                                                  68,717                                0.01%
 Roy Davis     40,295                                                  40,295                                0.01%

 

The shares element of the Non-Executive Directors' remuneration for 2025 will
be awarded at 32.17 pence per Ordinary Share, being the average closing
mid-market price of the last 10 trading days of 2024. The Non-Executive
Directors will receive these shares in January 2026.

 

Total Voting Rights

 

Application has been made to the London Stock Exchange and it is anticipated
that trading of the new Ordinary Shares will commence on AIM at 8:00am on 16
January 2025.

 

Immediately following the above issue, the Company will have 303,829,684
ordinary shares in issue, each carrying one voting right. Since the Company
currently holds no shares in treasury, the total number of voting rights in
the Company is therefore 303,829,684 and this figure may be used by
Shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change in
their interest in, the share capital of the Company under the FCA's Disclosure
Guidance and Transparency Rules.

 

Further details are contained within the notifications below, made in
accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full
details of the Non-Executive Directors' remuneration will be included in the
Company's Annual Report & Accounts.

ENDS

 

Contacts:

 Futura Medical plc              James Barder                                            investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                 Chief Executive Officer

                                                       +44 (0)1483 685 670
                                 Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                 Finance Director and COO

 Panmure Liberum                 Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser               Rupert Dearden (Corporate Broking)

 and Broker

 Stifel Nicolaus Europe Limited  Alan Selby                                              +44 (0)207 710 7600

 Joint Broker                    Ben Maddison

 Alma Strategic Communications   Rebecca Sanders-Hewett                                  +44 (0)20 3405 0205

                                 Sam Modlin                                              futura@almastrategic.com

                                 Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon. Our core strength lies in our
research, development and commercialisation of topically delivered gel
formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the
treatment of Erectile Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant unmet needs
in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe. Eroxon has been nominated for a number
of healthcare industry awards and has won two to-date.

 

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Jeff Needham

 2    Reason for the notification
 a)   Position/status                                              Director/ PDMR

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Futura Medical plc

 b)   LEI                                                          21380053QLT46UNV2303

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument

                                                                   Ordinary shares of 0.2p each

      Identification code

                                                                   GB0033278473
 b)   Nature of the transaction                                    Issue of shares

 c)   Price(s) and volume(s)

Price(s)     Volume(s)

                                                                   27.10 pence  55,600
 d)   Aggregated information

      - Aggregated volume

                                                                   Not applicable

      - Price

 e)   Date of the transaction                                      16 January 2025

 f)   Place of the transaction                                     Outside of trading venue

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

16 January 2025

f)

 

Place of the transaction

 

Outside of trading venue

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Andrew Unitt

 2    Reason for the notification
 a)   Position/status                                              Director/ PDMR

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Futura Medical plc

 b)   LEI                                                          21380053QLT46UNV2303

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument

                                                                   Ordinary shares of 0.2p each

      Identification code

                                                                   GB0033278473
 b)   Nature of the transaction                                    Issue of shares

 c)   Price(s) and volume(s)

Price(s)     Volume(s)

                                                                   27.10 pence  30,221
 d)   Aggregated information

      - Aggregated volume                                          Not applicable

      - Price

 e)   Date of the transaction                                      16 January 2025

 f)   Place of the transaction                                     Outside of trading venue

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

16 January 2025

f)

 

Place of the transaction

 

Outside of trading venue

 

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Roy Davis

 2    Reason for the notification
 a)   Position/status                                              Director/ PDMR

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Futura Medical plc

 b)   LEI                                                          21380053QLT46UNV2303

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument

                                                                   Ordinary shares of 0.2p each

      Identification code

                                                                   GB0033278473
 b)   Nature of the transaction                                    Issue of shares

 c)   Price(s) and volume(s)

Price(s)     Volume(s)

                                                                   27.10 pence  40,295
 d)   Aggregated information

      - Aggregated volume

                                                                   Not applicable

      - Price

 e)   Date of the transaction                                      16 January 2025

 f)   Place of the transaction                                     Outside of trading venue

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

16 January 2025

f)

 

Place of the transaction

 

Outside of trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFZGMMVGNGKZM